ClinicalTrials.gg
RecruitingNCT06839898Updated Feb 21, 2025

A Prospective, Randomized Clinical Study of Two Phakic Toric Implantable Lenses

An interventional study of EYECRYLTM Phakic Toric Intraocular Lens Treatment Arm and Visian® Toric ICL Treatment Arm in Myopia, Moderate, Myopic Astigmatism and Myopia, Degenerative, sponsored by Biotech Healthcare Holding Gmbh. Recruiting at 4 sites in 2 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2025-02-21.

Primary conditionMyopia, DegenerativeRegistry: MyopiaReclassifiedWhy we changed it
Registry
Myopia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Myopia, Degenerative
Why
  1. The study's listed conditions name Myopia, Degenerative, a narrower term within Myopia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Biotech Healthcare Holding Gmbh · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Registered 3 years 2 months after the study started (first participant enrolled Oct 2021, registered Jan 2025).
  • Started Oct 2021; still recruiting 5 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

Primary Objective: To compare the efficacy and the residual refractive error of EYECRYLTM Phakic toric versus Visian® Toric ICL in moderate to high myopic patient with co-existing astigmatism. Secondary Objectives: To evaluate and compare the safety of EYECRYLTM Phakic toric versus Visian® Toric ICL in moderate to high myopic patients with co-existing astigmatism.

Read the detailed description

Phakic intraocular lenses are clear implantable lenses that are surgically placed either in anterior chamber (AC) or posterior chamber (PC) without removing the natural lens, enabling light to focus on the retina for improved uncorrected visual acuity. Phakic intraocular lenses demonstrate high optical quality and potential gain in visual acuity in myopic patients due to retinal magnification. Toric version of phakic intraocular lens is intended to correct both myopia and astigmatism.1

02

Conditions studied

  • Myopia, Moderate
  • Myopic Astigmatism
  • Myopia, Degenerative

Browse trials for

03

In context

Myopia, Degenerative Reclassified

71 studies on the registry are indexed under Myopia, Degenerative; 20 are open to participants now.

This study's planned enrollment of 172 is above the median of 122 across 57 interventional studies indexed under Myopia, Degenerative.

Browse Myopia, Degenerative studies →

Lead sponsor

Biotech Healthcare Holding Gmbh is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Compared within Myopia, Degenerative, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Myopia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 21 years old or older.
  • Calculated IOL Power is within the range of the IOLs
  • Corneal Cylindrical error within the range defined in the clinical investigation plan
  • Subject has monocular UCVA 0.5 LogMAR or worse
  • Subject has had a stable refraction (±0.5D; ±1.0D for higher refractive errors), as expressed by manifest refraction spherical equivalent (MRSE) for a minimum 12 months prior to surgery, verified by consecutive refractions and/or medical records or prescription history.
  • Subject, who is a current contact lens wearer, needs to demonstrate a stable refraction (±0.5D) expressed as MRSE, on two consecutive examination dates and stability of the refraction is determined by the following criteria:

    1. Contact lenses were not worn for at least 2 weeks or 3 days prior to the first refraction.
    2. Two refractions were performed at least 7 days apart.
  • Subject, who is expected to have residual postoperative cylindrical refractive error of ≥1D, has been given the opportunity to experience his/her best spectacle vision with the anticipated correction.
  • Expected dilated pupil size at least large enough to visualize the axis marking.
  • Patients willing to attend all follow-up appointments
  • Patients must sign and be given a copy of the written form

Exclusion criteria

Exclusion Criteria:

  • Subject with acute and chronic disease or illness that would increase the operative risk or confound the outcomes of the evaluation.
  • Subject taking systematic medication that can confound the outcome of the study or increase the risk to the subject
  • Subject with ocular condition that may predispose the subject to future complications
  • Subject with previous intraocular or corneal surgery
  • Subject with less than the minimum endothelial cell density 2000 cells/mm² at the time of enrollment
  • Pregnant or planning to become pregnant, or is lactating during the course of the evaluation
  • Other condition associated with fluctuation of hormones
  • ACD measured from the endothelium lower than 2.8 mm
  • Concurrent participation in another drug or device evaluation.
  • Any cataract of any grade.
  • Coefficient of variation of endothelial cell area >0.45
  • Percent Hexagonality of endothelial cell shape ≤ 45%
  • Monocular subject
  • Vulnerable subjects as defined in section 12.3.10
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
172 participants (estimated)

Study arms

  • Experimental
    EYECRYLTM Phakic Toric Intraocular Lens Treatment Arm

    Patients will be implanted with Eyecryl Phakic Toric IOL based on randomization.

    Device: EYECRYLTM Phakic Toric Intraocular Lens Treatment Arm

  • Active comparator
    Visian® Toric ICL Treatment Arm

    Patients will be implanted with Visian® Toric ICL based on randomization.

    Device: Visian® Toric ICL Treatment Arm

Interventions

  • DeviceEYECRYLTM Phakic Toric Intraocular Lens Treatment Arm

    The patients will be implanted with Eyecryl Phakic IOL at this arm based on randomization.Phakic intraocular lenses are clear implantable lenses that are surgically placed either in anterior chamber (AC) or posterior chamber (PC) without removing the natural lens, enabling light to focus on the retina for improved uncorrected visual acuity. Phakic intraocular lenses demonstrate high optical quality and potential gain in visual acuity in myopic patients due to retinal magnification. Toric version of phakic intraocular lens is intended to correct both myopia and astigmatism.

  • DeviceVisian® Toric ICL Treatment Arm

    The patients will be implanted with Visian® Toric Implantable Contact Lens at this arm based on randomization. Phakic intraocular lenses are clear implantable lenses that are surgically placed either in anterior chamber (AC) or posterior chamber (PC) without removing the natural lens, enabling light to focus on the retina for improved uncorrected visual acuity. Phakic intraocular lenses demonstrate high optical quality and potential gain in visual acuity in myopic patients due to retinal magnification. Toric version of phakic intraocular lens is intended to correct both myopia and astigmatism.

06

What researchers measure

Primary outcomes

  1. The mean residual refractive error

    The mean residual refractive error in the study lens population that is equivalent to the mean residual refractive error of the control lens within +/- 0.50 Diopters at the 6-months post-op visit.

    Time frame: 6 Month

07

Study locations

4 of 4 sites recruiting
  • Precise Vision Augentagesklinik Greven
    Münster, Nordrhein-Westfalen 48268, Germany
    Recruiting
  • Precise Vision Augentagesklinik Rheine
    Rheine, Nordrhein-Westfalen 48429, Germany
    Recruiting
  • Precise Vision Augentagesklinik Rheine
    Steinfurt, Nordrhein-Westfalen 48429, Germany
    Recruiting
  • Netradhama Superspeciality Eye Hospital
    Bangalore, Karnataka 560 082, India
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Aug 2025, 46 months after the start.

Of 30 interventional studies with no phase under Myopia, Degenerative, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 96. This study's planned 46 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2025
First posted
Feb 21, 2025
StartActual
Oct 10, 2021
Primary completionEst.
Aug 2025
CompletionEst.
Feb 2027
Last update
Feb 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06839898
Lead sponsor
Biotech Healthcare Holding Gmbh
Responsible party
Sponsor
First posted
Feb 21, 2025
Start date
Oct 10, 2021
Primary completion
Aug 2025 (estimated)
Completion
Feb 2027 (estimated)
Last update
Feb 21, 2025

Study contacts

BHARGAV D JOSHI, M.Sc.
Contact
bhargav.joshi@biotechhealthcare.com
917966823000 ext. 203
Hatice B Deveci Summer, B.Sc
Contact
basak.deveci@biotechhealthcare.com
0491739106424

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion